ImmunoGen cuts deep to eke out cash for mirvetuximab trial

ImmunoGen is set to layoff 220 employees and stop some R&D activities. The deep cuts are designed to make ImmunoGen’s $240 million cash pile last past the delivery of phase 3 mirvetuximab data in the first half of 2022